Laigo Bio

Laigo Bio is a Seattle-based biotechnology company specializing in the development of de novo protein therapeutics. Co-founded by Dr. Longxing Cao and Dr. David Baker from the University of Washington's Institute for Protein Design, the company leverages the 'Ligo' computational framework to design highly stable and specific miniproteins. These synthetic molecules are engineered to modulate biological targets, such as cytokines and cell-surface receptors, which are often difficult to address with conventional antibodies. Laigo Bio's platform aims to create a new class of medicines with improved tissue penetration and modularity for applications in oncology and autoimmune diseases. The company is backed by prominent venture capital firms including ARCH Venture Partners and Madrona.